Breast cancer (BC) is a leading cause of death between women. Mortality is significantly raised due to drug resistance and metastasis, while personalized treatment options are obstructed by the limitations of conventional biopsy follow-up. Lately, research is focusing on circulating biomarkers as minimally invasive choices for diagnosis, prognosis and treatment monitoring. Circulating cell-free DNA (ccfDNA) is a promising liquid biopsy biomaterial of great potential as it is thought to mirror the tumor’s lifespan; however, its clinical exploitation is burdened mainly by gaps in knowledge of its biology and specific characteristics. The current review aims to gather latest findings about the nature of ccfDNA and its multiple molecular and biological characteristics in breast cancer, covering basic and translational research and giving insights about its validity in a clinical setting.
Yahya Mahamat‐Saleh, Alicia K. Heath, Vivian Viallon, Antonio Agudo, Giovanna Masala, Salvatore Panico, Carlotta Sacerdote, Karl Smith‐Byrne, Ruth C. Travis, Rosario Tumino, Martijn Kolijn, Roel Vermeulen, Nicholas J. Wareham, Pietro Ferrari, Elio Riboli, Marc J. Gunter, Laure Dossus
Nikos Papadimitriou, Niki Dimou, Dipender Gill, Ioanna Tzoulaki, Neil Murphy, Elio Riboli, Sarah Lewis, Richard M. Martin, Marc J. Gunter, Konstantinos K. Tsilidis
Jorge Gómez‐Miragaya, Sebastián Morán, María Eréndira Calleja-Cervantes, Alejandro Collado-Solé, Laia Paré, Antonio Gómez, Violeta Serra, Lacey E. Dobrolecki, Michael T. Lewis, Ángel Díaz‐Lagares, Pîlar Eroles, Aleix Prat, Manel Esteller, Eva González‐Suárez
Discussion(0)
No comments yet. Be the first to comment.